摘要
目的观察普萘洛尔在家族性肝癌肝动脉栓塞化疗(transcatheter arterial chemoembolization,TACE)围术期应用的安全性和近期疗效。方法 TACE术前3天开始口服普萘洛尔,自10mg/次起,逐日增加5mg至20mg/次,3次/天,术后继续口服普萘洛尔共4w。结果 9例患者共接受TACE治疗21次,平均2.3次(1~4次)。9名患者均可评价疗效,其中CR2例,PR4例,SD1,PD2例,RR67.7%(6/9)。6个月生存率88.9%(8/9),12个月生存率66.7(6/9),18个月生存率33.3%(3/9)。介入并发症主要有呕吐1例,腹痛6例,发热4例。毒副反应中性粒细胞Ⅲ抑制1例,无Ⅳ度抑制。结论普萘洛尔在家族性肝癌患者TACE围术期应用的近期有效率67.7%,未观察到严重和特别的并发症及毒副反应。
Objective: To observe recent efficacy and safety of propranolol taken orally the familial genetics patients with primary liver cancer(PLC) during the perioperative period in transcatheter arterial chemoembolization(TACE).Methods: Totally 9 familial genetics patients with PLC had taken orally propranolol the third day before TACE for four weeks,propranolol 20mg one time and three times one day.Results: The response rate was 67.7%(6 /9) by Response Evaluation Criteria in Solid Tumors(RECIST).CR,PR,SD,PR were respectively 2,4,1,2 cases.The 6-month,12-month and 18-month survival rates were respectively 88.9%(8 /9),66.7(6 /9),33.3%(3 /9).Complication were 1 case of vomiting,6 cases of abdominal pain,4 cases of fever.Adverse reactions included 1 case of Ⅲ degree neutropenia inhibition.Conclusion: The familial genetics patients with PLC had taken orally propranolol during the perioperative period in TACE that was efficacy and safety.
出处
《中国优生与遗传杂志》
2013年第7期134-135,63,共3页
Chinese Journal of Birth Health & Heredity
关键词
肝癌
家族性
肝动脉栓塞化疗术
普萘洛尔
近期疗效
安全性
Primary liver cancer
Familial genetics
Transcatheter arterial chemoembolization
Propranolol
Recent efficacy
Safety